Compare PRA & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRA | BLFS |
|---|---|---|
| Founded | 1976 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | N/A | 1989 |
| Metric | PRA | BLFS |
|---|---|---|
| Price | $24.08 | $24.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $22.50 | ★ $31.50 |
| AVG Volume (30 Days) | ★ 479.6K | 337.5K |
| Earning Date | 02-23-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $1,120,385,000.00 | $100,144,000.00 |
| Revenue This Year | N/A | $20.67 |
| Revenue Next Year | $1.24 | $14.13 |
| P/E Ratio | $36.62 | ★ N/A |
| Revenue Growth | N/A | ★ 87.53 |
| 52 Week Low | $13.90 | $19.10 |
| 52 Week High | $24.41 | $29.62 |
| Indicator | PRA | BLFS |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | 47.06 |
| Support Level | $24.02 | $23.58 |
| Resistance Level | $24.16 | $26.68 |
| Average True Range (ATR) | 0.09 | 0.88 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 26.92 | 41.13 |
ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in five segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.